What the changes say
- Lexaria faces severe going concern doubts with only $1.8 million in cash against $1.5 million in liabilities, threatening operations.
- Growth depends heavily on costly R&D to prove DehydraTECH works with new APIs and molecules.
What changed since the prior 10-K
New
- New
There is substantial doubt as to our ability to continue as a going concern, which may affect our ability to obtain future financing and may require us to curtail or cease our operations
Substantial doubt about the company's ability to continue as a going concern threatens future financing and may force liquidation.
Reworded
- 23% rewritten
The longer-term growth of our business depends on our ability to expand our portfolio of patents and industry segments where DehydraTECH is demonstrably applicable, which may require substantial financial resources and may ultimately be unsuccessful
The risk was tightened to focus specifically on the R&D required to prove DehydraTECH's efficacy works with other APIs and molecules.
All 26 risk factors
Headings as the filing states them, in filing order.
Other
- 01DehydraTECH-enabled pharmaceutical products may not successfully proceed to commercialization
- 02If we are unable to retain and hire qualified personnel, we may not be able to implement our business plan successfully
- 03We face substantial competition, which may result in others discovering, developing and/or commercializing technology or products similar to ours before or more successfully than us
- 04Any failure in protecting our intellectual property may have a negative impact on our ability to develop and license DehydraTECH
- 05Technological R&D in the bioscience industry involves a lengthy, expensive process with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete our studies or trials
- 06regulators may require the submission of additional data or impose other requirements before granting permission to proceed
- 07If we are unable to obtain and maintain sufficient patent protection, or if the scope of the patent protection is not sufficiently broad, our competitors could develop technology similar to ours
- 08We are dependent on the services of third parties and unsatisfactory performance will negatively affect our Company
- 09Any failure to prevent or mitigate security breaches and improper access to or disclosure of our data or our user data could result in the loss or misuse of such data, which could harm our business and reputation and diminish our competitive position
- 10We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed alleged trade secrets
- 11There is substantial doubt as to our ability to continue as a going concern, which may affect our ability to obtain future financing and may require us to curtail or cease our operationsNew
- 12Without additional financing to develop our business plan, our business may fail
- 13The longer-term growth of our business depends on our ability to expand our portfolio of patents and industry segments where DehydraTECH is demonstrably applicable, which may require substantial financial resources and may ultimately be unsuccessful23% rewritten
- 14We may enter into collaborations with third parties for the development and commercialization of our product candidates. If we fail to enter into such collaborations, or such collaborations are not successful, we may not be able to capitalize on the market potential of our product candidates
- 15view product candidates discovered in collaboration as competitive with their existing product candidates or products. They may cease to devote resources to the development of collaborative product candidates
- 16Our product candidates are in an early stage of development and may fail or experience significant delays or may never advance to the clinical stage, which may materially and adversely impact our business
- 17Pharmaceutical products incorporating DehydraTECH have never been approved for the treatment of disease
- 18Any success achieved at a given stage of the clinical trials does not guarantee that the future achievement of success at any subsequent stage, including without limitation, final FDA or comparable regulatory authority approval
- 19Pharmaceutical products using CBD as an API have limited approval for the treatment of any disease
- 20Regulation of non-pharmaceutical hemp-based CBD products is evolving
- 21Controlled substance legislation differs between localities. Legislation in certain jurisdictions may restrict or limit our ability to develop and commercialize products using DehydraTECH
- 22The trading price of the shares of our common stock could be highly volatile and as such investors could incur substantial losses
- 23Our by-laws do not contain anti-takeover provisions, which could result in a change of our executive management and directors if there is a take-over of our Company
- 24We do not intend to pay any dividends on our shares
- 25Purchasers of our shares may incur dilution
- 26We are a “smaller reporting company” under the SEC’s disclosure rules and have elected to comply with the reduced disclosure requirements applicable to smaller reporting companies
Other Lexaria Bioscience 10-Ks
- FY2024 10-K risk factors25 risks
Lexaxia relies heavily on the success, patent protection, and regulatory approval of its DehydraTECH drug delivery technology. The company faces significant financial constraints, early-stage preclinical pipeline risks, and evolving regulations governing cannabinoid products.
Filed Nov 26, 2024
About this page
The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.